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Abstract
Background: Significant peripheral blood CD4+ T-cell depletion has been observed after a first cycle of rituximab, a
monoclonal antibody directed against the CD20 antigen, which is currently used in rheumatoid arthritis. Of note, an
absence of CD4+ T-cell decrease has been observed in non-responders. Herein, we describe CD4+ T-cell changes
over repeated cycles of rituximab and their relationship with clinical outcomes.
Methods: Patients with rheumatoid arthritis who started rituximab between July 2007 and July 2013 were analyzed
up to November 2014. Lymphocyte phenotyping and clinical assessments were performed before, and 3 and
6 months after each cycle. Lymphocytes counts and disease activity were compared at each time point, using
nonparametric tests.
Results: Patients received up to seven cycles of treatment during the study period. Mean CD4+ T-cell counts were
above the upper limit of the reference range before each rituximab infusion and repeatedly reached the reference
range at 6 months (and/or 3 months) post infusion. CD4+ T cells decreased concurrently with disease activity score.
Conclusions: CD4+ T-cell counts could be a relevant biomarker of response to rituximab in rheumatoid arthritis
and could be considered in making decisions about the timing of retreatment.
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Background
Targeting B cells with rituximab (RTX), a chimeric
monoclonal antibody directed against the CD20 antigen,
induces a sustained clinical improvement in most
patients with rheumatoid arthritis (RA) [1, 2]. Patients
who respond to treatment are likely to receive multiple
repeated cycles of RTX upon relapse.
RTX leads to depletion of both normal and autoreac-
tive B cells and this effect is almost complete in blood
and partial in bone marrow [3–7]. The latter population
is responsible for the production of rheumatoid factor
(RF) and anti-citrullinated protein antibodies (ACPAs),
both hallmarks of RA. Although some studies have
shown that RF [8, 9] or ACPA [8] positivity are associ-
ated with clinical response, RTX is also effective in the
RF-negative and ACPA-negative forms of RA. Addition-
ally, Cambridge et al. observed a post-RTX decrease in
RF and ACPA but neither the pre-treatment levels nor
the changes observed after treatment were predictive of
response to treatment [10]. These data suggest that the
efficacy of RTX in RA may depend on B-cell functions
unrelated to autoantibody production.
We and others previously reported significant deple-
tion of CD4+ T cells in peripheral blood in patients
receiving a first cycle of RTX for treatment of RA [11, 12].
Interestingly, patients who were non-responders to this
first cycle tended to experience a milder depletion of
CD4+ T cells than responders, whereas depletion of B
cells was similar in both groups. However, the relationship
between changes in CD4+ T cells and clinical outcomes
over repeated cycles of RTX has not been studied. The
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aim of the present study was to describe and characterize
the changes in CD4+ T cells over multiple, repeated cycles
of RTX and to investigate the potential relationship
between these changes and disease activity.
Methods
Patients and study protocol
Patients seen in routine clinical practice, who started
RTX for the treatment of RA between July 2007 and July
2013, were included in this retrospective study. The
present study is based on data collected during follow
up to November 2014. Therefore, some patients in-
cluded at the end were not followed up for as long as
those who were recruited at the beginning. Patients
received two infusions of 1000 mg of RTX as previ-
ously described. Clinical improvement (measured by the
Disease Activity Score in 28 joints using erythrocyte sedi-
mentation rate (DAS 28-ESR) and clinical tolerance were
assessed 3 months (M3) and 6 months (M6) post infusion
[11]. Radiographs were available at baseline, but radio-
graphic progression was not assessed systematically. Per-
cycle clinical response using European League Against
Rheumatism (EULAR) criteria was calculated for each pa-
tient relative to the baseline DAS 28-ESR of the first cycle
[13]. Decisions about retreatment and treatment intervals
were based on clinical response to the previous cycle and
symptoms of relapse after M6 (as-needed basis). Lympho-
cyte phenotyping was carried out before each infusion and
at follow-up visits as per routine procedure, without add-
itional sampling.
Lymphocyte phenotyping by flow cytometry
Lymphocyte phenotyping was performed as previously
described according to a standard no-wash, whole-blood
procedure using a PrepPlus and a TQ-Prep workstation
or a FP1000 workstation (Beckman Coulter) and an
Epics XL-MCL or a Navios flow cytometer (Beckman
Coulter) [11].
Statistical analysis
Statistical analysis was performed using GraphPad
Prism® software (version 6.0 for Macintosh; GraphPad
Software, San Diego, CA, USA). Wilcoxon’s matched-
pairs signed rank test was used for analysis of paired
data and differences in continuous variables between
non-paired data were assessed using the Mann–Whitney
nonparametric test. Results are presented as median and
range (minimum (min)-maximum (max)) or interquar-
tile range (IQR) for continuous variables. Kaplan-Meier
curves were used to study the persistence of patients
under rituximab. The significance level was set at 5 %
(p < 0.05).
Results
Mean global disease activity, CD19+ B-cell and CD4+
T-cell counts over multiple cycles of RTX
Fifty-four patients started RTX during the study period.
Patients’ characteristics are presented in Table 1. The
time interval between each cycle is presented in Fig. 1.
Maintenance to treatment is presented in Fig. 2. Median
time to RTX discontinuation was 42 months. Adverse
events were responsible for discontinuation in 4 of the
54 patients after the first cycle. Changes in disease
activity and lymphocyte counts over repeated cycles of
RTX are presented in Fig. 3. For each cycle, values are
presented at three time points, i.e. before the first infu-
sion, before the second infusions two weeks apart and at
3 or 6 months thereafter. All but one patient received
methylprednisolone.
Repeated RTX treatment led to sustained clinical im-
provement with the mean post-treatment DAS28-ESR
tending to decrease with the number of cycles (Fig. 3a).
Clinical improvement was delayed with B-cell depletion,
the latter being achieved before the second infusion in
most patients (Fig. 3b). Whilst the cycle 1 pre-treatment
B-cell count was within the normal reference range, it
remained substantially below the lower limit of the
reference range (<200/mm3) thereafter, and tended to
decrease with the number of cycles. Hence, patients
Table 1 Baseline characteristics of the 54 patients
Characteristics Baseline value
Age, years 60 (36–84)
Sex, n (%) female 42 (78)
Disease status
Disease duration, years 16 (1–36)
Disease Activity Score in 28 joints-erythrocyte
sedimentation rate
5.3 (2.1–7.7)
Erythrocyte sedimentation rate, mm/h 33.4 (3.0–111.0)
C-reactive protein, mg/L 17 (1–166)
Rheumatoid factor positivity, n (%) 38 (70)
Anti-cyclic citrullinated peptide positivity, n (%) 47 (87)
Radiologic evidence of erosions, n (%) 42 (78)
Previous treatment, n (%)




CD19+ cells/mm3 211 (25–706)
CD3+ cells/mm3 1,740 (323–3,378)
CD4+ cells/mm3 1,192 (233–2,882)
CD8+ cells/mm3 482 (120–1,114)
Values are the median (min–max) unless stated otherwise
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were usually retreated before recovery of the circulating
B-cell pool.
The changes occurring in CD4+ T-cell counts were
somewhat different (Fig. 3c). First, mean CD4+ T-cell
counts before RTX infusions were systematically above
the upper limit of the reference range (>1100/mm3).
They were higher in women than in men (p < 0.01), in
patients without RF than in those with RF (p < 0.04), in
patients without radiologic evidence of erosion than in
those with evidence of erosion (p < 0.03) and in RTX
first-cycle responders than in non-responders (p < 0.03).
Of note, there was a trend towards higher pre-treatment
CD4+ T-cell counts in patients previously treated with
TNF inhibitors as compared to patients not previously
treated (p < 0.09). Second, the mean post-treatment
counts (M3 or M6) were substantially decreased (within
the reference range), regardless of the cycle. The
decreased CD4+ T-cell counts were independent of sex,
RF and ACPA status, erosion status and co-medication
with corticosteroids or methotrexate (data not shown).
The decrease was delayed compared to B-cell depletion
and was closely related to clinical improvement. Of note,
there was no correlation between the CD4+ T-cell count
and DAS28 at baseline (data not shown). Finally, CD4+
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Fig. 1 Time interval between each rituximab cycle. Results are
presented as median and interquartile range
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Fig. 3 Changes in Disease Activity Score in 28 joints-erythrocyte
sedimentation rate (DAS28-ESR) (a), CD19 + B cells (b) and CD4+ T
cells (c) over seven cycles of rituximab (RTX). For each cycle, values
are presented at three time points, i.e. before the first infusion, before
the second infusions two weeks apart and at 3 or 6 months post
treatment. Results are shown as the median and interquartile range
in patients with available data. The level defining low disease activity is
represented (DAS28 ≤ 3.2). The limits of the reference range are
represented for CD19+ B cells (between 200 and 400/mm3) and for
CD4+ T cells (between 700 and 1100/mm3)
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Table 2 DAS28, CD 19+ cell count, CD4+ cell count at baseline, post treatment (M3/M6) and at the time of retreatment during the first cycle in 32 patients who received a
second cycle of rituximab
DAS28-ESR CD19+ (cells/mm3) CD4+ (cells/mm3)
Pre-treatment Post treatment Retreatment Pre-treatment Post treatment Retreatment Pre-treatment Post treatment Retreatment
Men (n = 7) 5.4 (4.1–6.0) 4.4 (2.0–5.1) 3.8 (3.2–5.3) 180 (45–237) 9 (0–87)* 50 (3–138)* 962 (703–1047) 652 (393–853) 1146 (702–1412)
Women (n = 25) 5.2 (4.6–6.2) 3.3 (2.7–4.7)** 4.6 (3.8–5.9)** 320 (179–411) 3 (0–36)** 44 (11–171)** 1329 (1015–1873) 988 (772–1498)** 1325 (964–1549)*
RF + (n = 22) 5.3 (4.3–6.1) 3.6 (2.6–5.1)** 4.3 (3.5–5.5) 271 (124–387) 3 (0–21)** 47 (10–134)** 1041 (908–1640) 875 (603–1305)* 1033 (826–1513)
RF – (n = 10) 5.2 (4.7–6.3) 3.3 (3.1–4.6)* 4.6 (3.6–5.8)* 275 (191–386) 15 (0–55)** 45 (8–263)* 1442 (1121–2048) 1044 (864–1386)** 1376 (1212–1637)*
Erosion (n = 24) 5.8 (4.3–6.4) 3.7 (2.6–5.1)** 4.6 (3.5–5.8)* 233 (143–325) 3 (0–40)** 47 (7–131)** 1119 (953–1708) 998 (639–1514)** 1328 (927–1584)*
No erosion (n = 8) 5.0 (4.7–5.3) 3.4 (2.7–4.3)* 4.2 (3.5–5.4) 371 (147–541) 4 (1–38) 100 (22–229)* 1289 (912–2201) 939 (869–981)* 1112 (958–1345)*
TNFi (n = 27) 5.2 (4.5–6.3) 3.6 (2.7–5.0)** 4.3 (3.4–5.8)* 237 (141–332) 3 (0–30)** 44 (9–138)** 1248 (995–1732) 988 (652–1464)** 1331 (1029–1620)*
No TNFi (n = 5) 5.8 (4.4–6.0) 2.8 (2.4–5.0) 4.4 (3.9–5.0) 433 (244–523) 3 (1–256) 68 (8–360) 819 (739–1733) 691 (323–907) 918 (727–981)
Patients were grouped according to the following subgroups: men/women, rheumatoid factor (RF)+/RF-, erosion/no-erosion, previous TNF inhibitor (TNFi)/no previous TNFi. Results are presented as median and
interquartile range. DAS28-ESR Disease Activity Score in 28 joints-erythrocyte sedimentation rate. Wilcoxon’s matched-pairs signed rank test was used to compare values post treatment vs pre-treatment, and retreatment vs













re-treatment. Changes in DAS 28, CD19+ and CD4+
cells, according to categories of patients (i.e. men vs
women, RF+ vs RF-, erosion vs non-erosion, previous
TNF inhibitors vs no previous TNF inhibitors) during
the first cycle are presented in Table 2 for the 32
patients who received a second cycle.
Per-cycle variation in CD4+ T-cell counts induced by RTX
To more precisely describe the dynamic changes induced
by RTX, CD4+ cell counts were compared at three time
points in each cycle: pre-treatment, post treatment (i.e. at
M6 or at M3 if M6 data were unavailable) and retreatment
(i.e. before the first infusion of the next cycle). For these
per-cycle analyses, only retreated patients were included
(Fig. 4) in order to describe both decrease and recovery
phases. For all cycles except cycle 3 and cycle 6, mean
post-treatment CD4+ values were significantly lower than
mean pre-treatment or retreatment values. The mean post-
treatment count tended to decrease slightly upon repeated
cycles, reaching the lower limit of the reference range after
cycle 4. Furthermore, RTX led to dramatically decreased









































































Cycle 3 n = 19
NS

























































































































































Fig. 4 Per-cycle analysis of pre-treatment, post-treatment and retreatment counts of CD4+ T cells. In each cycle only patients for whom data were
available were included. Each dot represents one patient and lines represent the mean with SD. The limits of the reference range are presented
(between 700 and 1100/mm3). CD4+ cell counts were compared between the three points, i.e. before treatment, 3 or 6 months post treatment
and before retreatment for each cycle usingWilcoxon’s matched-pairs signed rank test: ****p < 0.0001, ***p < 0.001, **p < 0.005, *p < 0.05;
NS not significant
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in 8/54 patients (6 patients in the first cycle), including in
one patient who presented with extensive oropharyngeal
candidiasis. This effect was independent of the number of
cycles and of the previous cycle variation in CD4+ T-cell
counts. Finally, mean pre-treatment and retreatment
values were not significantly different. The changes in
CD4+ T-cell counts in the eight patients with a value of
<300/mm3 at least once during follow up are presented in
Fig. 5. The relationship between adverse events and
lymphocyte phenotyping will be studied in a separate re-
port, and therefore will not be presented in the present
article.
Clinical response and CD4+ T-cell changes observed
during cycle 2, in cycle 1 non-responders
We then focused on 10 patients who were retreated
despite a poor response in cycle 1. The DAS28-ESR and
CD4+ T-cell changes in these patients are shown in
Fig. 6a and c and those in initial responders in Fig. 6b
and d. Of the 10 responders, 8 initial non-responders
became responders after the second cycle. The cycle-2
post-treatment DAS28-ESR was decreased in these pa-
tients compared to cycle 2 pre-treatment and to cycle 1
pre-treatment and post treatment. In initial responders,
the post-treatment DAS28-ESR was similar in cycles 1
and 2 and CD4+ T-cell counts were significantly and
similarly decreased in both cycles. Conversely, in initial
non-responders, CD4+ T-cell counts remained the same
in cycle 1; however, in cycle 2 the post-treatment CD4+
T-cell counts tended to be lower than the pre-treatment
values in both cycle 1 and cycle 2 (p = 0.08 and p = 0.10,
respectively). Moreover, they were significantly de-
creased compared to cycle-1 post-treatment values, fur-
ther suggesting a potential relationship between disease
activity and CD4+ T-cell counts in patients with RA
receiving RTX.
Discussion
Repeated cycles of RTX are known to induce sustained
and sometimes improved efficacy in patients with RA
[14]. We show here that improved clinical response ob-









































































































Fig. 5 Changes in CD4+ T cell counts in patients (n = 8/54) who experienced at least one decrease in the CD4+ cell count to below 300/mm3
during follow up
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basis, was associated with repeated variation in CD4+ T-
cell counts occurring over successive cycles.
The first finding of this study was that the mean
CD4+ T-cell counts were above the upper limit of the
reference range at baseline and before each RTX cycle.
This result indicates that the homeostasis of CD4+ T cells
was disrupted before RTX treatment and when the
patients stopped responding. Interestingly, baseline CD4+
T-cell counts were significantly higher in responders than
in non-responders on the one hand, and in patients with-
out RF and in those without radiologic evidence of erosion
on the other hand. These results might suggest that
patients with less severe forms of the disease are more
likely to respond to RTX. However, until now only the
presence of RF [8, 9] or ACPA [8] has been identified as
predictor of clinical response. Larger studies are required
to confirm this conclusion and, eventually, to define a
predictive threshold of CD4+ T-cell counts value for
clinical response.
We have previously reported a substantial decrease in
CD4+ T-cell counts in a large majority of patients with
RA receiving a first cycle of RTX. A decrease in CD4+ T
cells was not observed in the absence of response follow-
ing the first cycle [11]. The present study shows that a
decrease in CD4+ T-cell counts occurred repeatedly
along with clinical response in patients who received up
to seven cycles of RTX. A slightly additive effect of
repeated treatment was seen, with the mean post-
treatment CD4+ T-cell count gradually reaching the
lower limit of the normal range. Additionally, we found
that a second cycle of RTX in initial non-responders led
to a clinical response in 8 of 10 patients. The improve-
ment in clinical response following this second cycle was
associated with a decrease in CD4+ T-cell counts, which
was not observed in the first cycle.
It is known that post-RTX B-cell recovery is a long
process [3–7, 15]. Therefore, patients are usually
retreated before complete recovery of the B-cell pool.
There was a tendency toward a decrease in pre-
treatment CD19+ B-cell counts with repeated cycles.
This may be due to a biologic effect of RTX, but it may

































































































































































































Fig. 6 Changes in Disease Activity Score in 28 joints-erythrocyte sedimentation rate (DAS28-ESR) (a, b) and CD4+ T-cell counts (c, d) over cycle 1
and cycle 2 in first-cycle non-responders (a, c) (n = 10) and in first-cycle responders (b, d) (n = 20). Pre-treatment and 3 or 6 months post-treatment
data are shown as scatter dot plots (first cycle non-responders n = 10; first-cycle responders, n = 20). Each dot represents one patient and lines represent
the mean with SD. For DAS28-ESR analysis, the level defining low disease activity is represented (DAS28 ≤ 3.2). Comparison of pre-treatment and
post-treatment values was made using Wilcoxon’s matched-pairs signed rank test: ****p < 0.0001, ***p < 0.001, **p < 0.005, *p < 0.05; NS not significant
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interval between each cycle that we observed. By
contrast, an RTX-induced CD4+ T-cell decrease was
followed by complete recovery of the circulating CD4+
T-cell pool at the end of each cycle. The time to CD4+
T cell recovery may vary across patients and may relate
to the time to relapse. Also we previously reported that
there was a greater decrease in the CD4+ T-cell count in
patients whose time to retreatment was >12 months
than in those whose time to retreatment was <12 months
[11]. The assumption that CD4 could be a valuable
marker is based on the coincidence between the clini-
cian’s decision whether to retreat and the CD4 recovery.
It is indeed very apparent that recovery of CD4+ cells
occurs at the time of the relapse. Taken together, these
results show that in patients with RA receiving RTX,
disease activity is more closely related to CD4+ T-cell
variations than to B-cell variations, suggesting that mon-
itoring CD4+ T cells might be more relevant for predict-
ing disease relapse. The present results reopen the issue
of re-treatment timing, and suggest that a scheme of
RTX administration based on CD4+ T-cell counts might
anticipate and eventually avoid disease relapse.
Conclusions
Repeated post-treatment decrease in CD4+ T-cell counts
over successive cycles of RTX occurs in patients with
RA. Changes in CD4+ T-cell counts could be a relevant
biomarker of RA activity in RTX-treated patients and
hence aid the determination of an appropriate treatment
schedule. The accuracy of CD4+ T-cell counts as a bio-
marker of disease activity and/or RTX efficacy needs to
be confirmed by further prospective studies.
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